Trials / Active Not Recruiting
Active Not RecruitingNCT05297903
XmAb20717 in Advanced Biliary Tract Cancers
Phase II Trial of XmAb20717 in Patients With Advanced Biliary Tract Cancers
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 27 (estimated)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, phase II clinical trial to evaluate the efficacy of XmAb20717 in patients with advanced biliary tract cancers who have progressed on, or were intolerant of, a gemcitabine-based chemotherapy regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XmAb20717 | 10mg/kg IV |
Timeline
- Start date
- 2022-04-11
- Primary completion
- 2026-12-02
- Completion
- 2026-12-02
- First posted
- 2022-03-28
- Last updated
- 2025-09-15
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05297903. Inclusion in this directory is not an endorsement.